Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advances in Automated Driving Systems
| Advances in Automated Driving Systems |
| Autore | Eichberger Arno |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 electronic resource (294 p.) |
| Soggetto topico |
Technology: general issues
History of engineering & technology |
| Soggetto non controllato |
automated driving
scenario-based testing software framework traffic signs ADAS traffic sign recognition system cooperative perception ITS digital twin sensor fusion edge cloud autonomous drifting model predictive control (MPC) successive linearization adaptive control vehicle motion control varying road surfaces vehicle dynamics Mask R-CNN transfer learning inverse gamma correction illumination instance segmentation pedestrian custom dataset deep learning wheel loaders throttle prediction state prediction automation safety validation automated driving systems decomposition modular safety approval modular testing fault tree analysis adaptive cruise control informed machine learning physics-guided reinforcement learning safety autonomous vehicles autonomous conflict management UTM UAV UGV U-Space framework development lane detection simulation and modelling multi-layer perceptron convolutional neural network driver drowsiness ECG signal heart rate variability wavelet scalogram automated driving (AD) driving simulator expression of trust acceptance simulator case study NASA TLX advanced driver assistant systems (ADAS) system usability scale driving school virtual validation ground truth reference measurement calibration method simulation traffic evaluation simulation and modeling connected and automated vehicle driver assistance system virtual test and validation radar sensor physical perception model virtual sensor model |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910580214003321 |
Eichberger Arno
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Anesthesia for Oncological Surgery
| Anesthesia for Oncological Surgery |
| Autore | Huang Jeffrey |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 |
| Descrizione fisica | 1 online resource (459 pages) |
| Altri autori (Persone) |
HuangJiapeng
LiuHenry |
| ISBN | 3-031-50977-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Preface -- Acknowledgments -- Contents -- Part I: Basic Science of Oncology -- Oncogenesis, What Is New? -- 1 Oncogenesis and Personalized Cancer Treatment -- 2 The Increasing Role of Immunotherapy -- 3 The Importance of Tissue Adequacy in Biomarker/Ancillary Studies Testing -- 3.1 Sequencing -- 3.2 Fluorescent In-Situ Hybridization (FISH) -- 3.3 RNA Gene Expression -- 3.4 Liquid Biopsies -- 4 The Environment, Chemicals, and Cancer -- 5 Microbial Oncogenesis -- References -- Epidemiology of Cancer -- 1 Introduction -- 2 Cancer Incidence and Trend -- 3 Lifetime Risk for Cancers -- 4 Survival Rates for Cancers -- 5 Cancer Mortality and Trend -- 6 Risk Factors for Cancers -- 7 Summary -- References -- Immunemodulation and Cancer -- 1 Introduction -- 2 Tumor Immunity -- 2.1 Tumor Immunity Require CD8+ T Cell Activation -- 2.2 T Cell Activation Require Antigen Presenting Cell -- 3 Antigen Presenting Cells and Cancer -- 3.1 Basic Biology of Dendritic Cells -- 3.2 DC Plays Pivotal Roles in Tumor Immunity -- 3.3 Cross Talk of DC with T Cells and NK Cells -- 4 Regulation DC by TLR Receptors -- 4.1 Basic Biology of Toll-like Receptors (TLRs) -- 4.2 TLRs Play a Pivotal Role in Bringing Innate and Adaptive Immunity -- 4.3 Antitumor Effect of TLR3 -- 4.4 Antitumor Effect of TLR7and TLR8 -- 4.5 Antitumor Effect of TLR9 -- 5 Activation of T Cell Mediated Tumor Immunity by Immune Check Point Inhibition -- 5.1 T Cell Mediated Tumor Immunity Is Regulated by Balance of Stimulatory and Inhibitory Receptors (Immune Checkpoints) -- 5.2 Programmed Cell Death Protein 1 and Programmed Cell Death Protein Ligand 1 (PD-1/PDL1) -- 5.3 CTLA-4 -- 5.4 TIM-3 -- 5.5 LAG-3 -- 6 The Tumor Microenvironment -- 6.1 Regulatory T Cells in the TME.
6.2 The Infiltration of Tumor Associated Macrophages and Myeloid-Derived Suppressor Cells in the TME -- 7 Summary -- References -- Cancer Targeted Molecular Therapy -- 1 Introduction -- 2 General Strategies for Identifying Cancer Molecular Targets -- 2.1 Conventional Strategies to Identify Specific Tumor Biomarkers -- 2.2 Next-Generation Sequencing (NGS) -- 3 Molecular Targets Associated with Cancer -- 3.1 Targeting ALK Pathway -- 3.2 Targeting BCL-2 Pathways -- 3.3 Targeting BRAF Pathways -- References -- CAR T-Cell Therapy -- 1 Introduction -- 2 FDA-Approved CAR T-Cell Therapies (Accurate as to the Time of Writing) -- 3 Anti-CD19 CAR T-Cells -- 4 Anti-BCMA CAR T-Cells -- 5 Pre-CAR T Cell Therapy Evaluation and Preparation -- 6 Therapy Process -- 7 Toxicities of CAR T-Cell Therapy -- 8 Common Operative Procedures -- 9 Preoperative Assessment -- 10 Anesthetic Management -- 11 Conclusion -- References -- Part II: Perioperative Oncology -- The Surgeon: Anesthesia Professional Relationship -- 1 Introduction -- 2 Operating Team: Anesthesia Team Dynamics -- 3 Surgeon: Anesthesia Professional Familiarity -- 4 Surgeon: Anesthesia Teams -- 5 Special Responsibilities for the Anesthesia Team: A Surgeons' Perspective -- 6 Operation Conduct -- 7 The Operative Team: Anesthesia Team Relationship with Operating Team -- 8 Conclusions -- Further Reading -- Anesthetic Technique and Cancer Recurrence -- 1 Introduction -- 2 Pathogenesis of Cancer Recurrence After Surgery -- 3 Immune Suppression After Surgery -- 4 Anesthetic Techniques and Impacts on Cancer Recurrence -- 4.1 Volatile Anesthetics -- 4.2 Total Intravenous Anesthetics (TIVA) -- 4.3 Total Intravenous Anesthetics (TIVA) Vs. Volatile Agents -- 4.4 Regional/Neuraxial Anesthetics -- 4.4.1 Local Anesthetics and Opioids -- 4.4.2 Regional Anesthesia. 4.4.3 Neuraxial Anesthetics -- References -- Prehabilitation -- 1 Introduction -- 2 Prehabilitation -- 3 Nutritional Optimization -- 4 Physical Fitness -- 4.1 Functionality -- 4.2 Physical Deconditioning -- 4.3 Treatment -- 4.4 Precautions to Exercise -- 5 Exercise Training -- 5.1 Mind Body Connection -- 6 Summary -- References -- Preoperative Evaluation and Preparations for Oncological Surgery -- 1 Introduction -- 2 Timing of the Preoperative Evaluation for Oncologic Surgery -- 2.1 Review of Medical History -- 2.2 Review of Oncologic History -- 3 Past Surgical History -- 4 Cardiac Evaluation and Estimation of Cardiac Risk -- 5 Pulmonary Evaluation -- 6 Endocrine Considerations -- 7 Pain Management -- 8 Frailty -- 8.1 Nutrition Assessment -- 9 Physical Exam -- 10 Summary -- References -- Perioperative Surgical Home, Enhanced Recovery After Surgery, and High-Risk Committee -- 1 Introduction -- 2 PSH Core Principles -- 2.1 Elements of the Perioperative Surgical Home -- 2.2 Adoption the PSH Model -- 2.3 The PSH Model for Cancer Patients -- 2.4 Enhanced Recovery After Surgery: Background -- 2.5 ERAS, Postoperative Outcomes and Cancer Outcome Studies -- 3 Peri-operative High-Risk Multidisciplinary Conference -- 4 Summary -- References -- Blood Management for Oncological Surgery -- 1 Introduction -- 2 Indications for Blood Transfusion in the Cancer Patient -- 3 Perioperative Measures to Reduce Blood Transfusion -- 4 Massive Transfusion Protocol -- 5 Transfusion-Related Complications -- 6 Transfusion and Cancer Outcomes -- 7 Conclusions -- References -- Acute Pain Service for Oncological Surgery -- 1 Acute Pain in Oncological Surgery -- 2 General Recommendations for Acute Pain Management in Oncological Surgeries -- 3 Special Considerations for Acute Postoperative Pain Management in Oncological Patients. 4 Acute Pain Management in Oncological Neurosurgery -- 4.1 Craniotomy -- 4.2 Spine Surgery -- 5 Acute Pain Management in Head and Neck Oncological Surgery -- 6 Acute Pain Management in Thoracic Oncological Surgery -- 7 Acute Pain Management in Abdominal, Gynecologic, and Urologic Oncological Surgery -- 7.1 Minimally Invasive Techniques (Laparoscopic/Robotic) -- 7.2 Open Abdominal Procedures -- 8 Acute Pain Management in Breast and Orthopedic Oncological Surgery -- 8.1 Breast -- 8.2 Orthopedic -- 8.3 Plastics: Free Flap -- 9 Acute Pain Management in Pediatric Oncological Surgery -- 9.1 Special Considerations -- 9.2 Regional Techniques -- 9.3 Summary -- 10 Postoperative Acute Pain Medical Management -- 10.1 Non-opioid Medications -- 10.2 Opioid Medications -- 11 Regional Analgesia Techniques for Various Types of Surgery -- 11.1 Head and Neck Surgery -- 11.2 Thoracic Surgery -- 11.3 Gastrointestinal, Gynecologic, and Urologic Oncologic Surgery -- 11.4 Breast Surgery -- 11.5 Upper and Lower Extremity Peripheral Nerve Blocks -- 11.6 Complications -- References -- Chronic Pain Clinic in Cancer Center and Oncological Services -- 1 Cancer Pain -- 1.1 Pain Management is Challenging -- 1.1.1 Healthcare Disparities -- 1.1.2 Professional Barriers -- 1.1.3 Patient Barriers -- 1.1.4 Societal Perception of Pain Management -- 1.2 Cancer Pain Management is Even More Challenging -- 2 Chronic Pain Clinics in Cancer Hospitals -- 2.1 Approach to Cancer Pain -- 2.2 Pain Assessment -- 2.3 Pharmacologic Therapy -- 2.3.1 Acetaminophen and Non-steroidal Anti-inflammatories (NSAIDs) -- 2.3.2 Antidepressants -- 2.3.3 Anticonvulsants -- 2.3.4 Opioids -- 2.3.5 Opioid Titration -- 2.3.6 Tolerance -- 2.4 Interventional Pain Modalities -- 2.4.1 Nerve Blocks -- 2.4.2 Nerve Ablations -- 2.4.3 Neuraxial Procedures. 2.5 Integrative Medicine -- 2.6 Psychosocial Interventions -- 3 Summary -- References -- Non pharmaceutics Therapy for Oncological Patients -- 1 Introduction -- 2 Physical Interventions -- 3 Psychosocial Interventions -- 4 Integrative Therapies -- 4.1 Herbal Products -- 4.2 Acupuncture -- 4.3 Massage -- 4.4 Yoga -- 4.5 Relaxation and Guided Imagery -- 4.6 Hypnosis -- 4.7 Meditation and Mindfulness -- 4.8 Other Mind Body Practices -- 4.9 Safety -- 5 Summary -- References -- Part III: Oncological Neurosurgery -- Craniotomy for Meningioma -- 1 Facts to Know -- 2 Pathology -- 3 Risk Factors -- 4 Screening -- 5 Diagnosis -- 6 Surgical Treatment -- 6.1 Strategies for Surgical Approaches -- 7 Common Complications -- 8 Medical Treatment -- 8.1 Adjuvant Radiation Treatment -- 8.2 Medical Treatment for Side Effects: [25] -- 9 Anesthesia Considerations -- 9.1 Preoperative Management -- 10 Intraoperative Management -- 11 Postoperative Management -- 12 Potential Concerns -- References -- Craniotomy for Glioma -- 1 Facts to Know -- 2 Pathology -- 3 Risk Factors -- 4 Screening -- 5 Diagnosis -- 6 Surgical Treatment -- 7 Key Surgical Steps -- 8 Dissection -- 9 Closure -- 10 Common Surgical Complications -- 11 Non-Surgical Treatment -- 11.1 Adjuvant Treatment -- 12 Anesthesia Considerations -- 12.1 Preoperative Management -- 12.2 Intraoperative Management -- 12.3 Postoperative Management -- 13 Potential Concerns -- References -- Craniotomy for Brainstem Tumors -- 1 Facts to Know -- 2 Pathology -- 3 Risk Factors -- 4 Screening -- 5 Diagnosis -- 6 Surgical Treatment -- 7 Orbitozygomatic Craniotomy Key Surgical Steps: [22, 23] -- 7.1 Positioning -- 7.2 Dissection -- 7.3 Craniotomy -- 7.4 Dural Opening and Cranial Approach -- 7.5 Reconstruction -- 8 Subtemporal Craniotomy Key Surgical Steps: [22, 23]. 8.1 Positioning. |
| Record Nr. | UNINA-9910842296303321 |
|
Huang Jeffrey
|
||
| Cham : , : Springer International Publishing AG, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Blood substitutes and oxygen biotherapeutics / / edited by Henry Liu, Alan D. Kaye, and Jonathan S. Jahr
| Blood substitutes and oxygen biotherapeutics / / edited by Henry Liu, Alan D. Kaye, and Jonathan S. Jahr |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (441 pages) |
| Disciplina | 617.96 |
| Soggetto topico | Anesthesiology |
| ISBN | 3-030-95975-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Blood Substitutes and Oxygen Biotherapeutics -- Is the Final Destination in the Long, Winding, Bumpy Road Finally in Sight? -- Contents -- Contributors -- Part I: Transfusion: Science and Practice -- 1: Erythrocyte Transfusion: Brief History and Current Practice -- Introduction -- Milestones in Erythrocyte Transfusion -- Karl Landsteiner and Discovery of Major Blood Groups -- The Early Years of Transfusion: The First Milestone -- Karl Landsteiner -- Balancing the Risks and Benefits of Anemia and Transfusion: The Second Milestone -- The Risks of Anemia -- The Target Organs of Anemia-Induced Injury -- Benefits and Risks of Erythrocyte Transfusion -- The Benefits of Transfusion -- The Risks of Transfusion -- Transfusion Reactions -- Transfusion Transmitted Infectious (TTI) Pathogens -- Transfusion-Attributable Adverse Outcomes -- Transfusion Avoidance and Blood Conservation -- The Search for an Objective Transfusion "Trigger" -- The Transfusion Requirements in Critical Care (TRICC) Study -- Restrictive vs Liberal Transfusion in Cardiac Surgery -- Patient Blood Management -- Summary and Conclusions -- References -- 2: Oxygen and ATP: the Energy Economy of the Cell -- Introduction -- Oxygen -- Adenosine Triphosphate -- ATP Production: An Overview -- Oxygen Utilization: An Overview -- The Cell's Energy Economy -- Aerobic Respiration -- Glycolysis -- In Summary -- Exceptional Case: Glycolysis in the Erythrocyte -- The Krebs Cycle -- Overview -- Some Details -- The Electron Transport Chain, Oxidative Phosphorylation -- Mitochondria -- Friend or Foe? -- The Energy Economy of Vital Organs -- The Heart -- The Brain -- Neurovascular Coupling -- Neurometabolic Coupling -- The Kidney -- The Liver -- Oxygen Sensing -- The Carotid Body Chemoreceptors -- HIF Mediators -- Cardiovascular System and Oxygen Supply Integration: The Role of NO.
In Summary -- "Bad" Oxygen Species -- Summary and Conclusions -- References -- 3: Physiological Functions of Blood -- Introduction -- Hematopoiesis -- Basic Physiology of the Components of Blood -- Transport of Oxygen and Carbon Dioxide -- Transport of Hormones, Nutrients and Metabolic Waste -- Hemostasis and Coagulation -- Immune System -- Acid-Base Regulation -- Thermoregulation -- Regulation of Body Fluids -- Conclusion -- References -- 4: Hemoglobin: Physiology and Hemoglobinopathy -- Introduction -- Hemoglobin and Oxygen Binding Regulation -- Oxygen Binding -- 2,3-DPG -- Hemoglobinopathies -- Thalassemia Syndromes -- Sickle Cell Disease -- Summary -- References -- 5: The Global Burden of Anemia -- Introduction -- Anemia Development and Classification -- Health and Societal Implications of Anemia -- Summary -- References -- 6: Blood Component Therapy: The History, Efficacy, and Adverse Effects in Clinical Practice -- Introduction -- Red Cell Components -- Red Blood Cell Concentrates -- Collection and Processing -- Principles of Preservation -- RBC Storage Lesions -- Metabolic Impairment -- Oxidative Injury -- Membrane Asymmetry -- Vesiculation -- Decreased Deformability -- Physiological Considerations -- Hemolysis -- Oxygen Delivery -- Hemostasis and Thrombosis -- Immunomodulation -- Clinical Outcomes -- Component Therapy: All Things "Yellow" -- Plasma Transfusions -- The Origin of Plasmapheresis Leading to Fresh Frozen Plasma -- Cryoprecipitate -- Platelets -- Platelet Activation and Adherence -- References -- 7: Allogeneic Blood Transfusion: Complications and Side Effects -- Introduction -- Infectious Complications -- Human Immunodeficiency Virus -- Hepatitis C Virus -- Hepatitis B Virus -- Septic Transfusion Reactions -- Immune-Mediated Complications -- Hemolytic Transfusion Reaction -- Allergic/Anaphylactic Complications. Allergic Transfusion Reactions -- Anaphylactic Transfusion Reactions -- Febrile Transfusion Reactions -- Cardiac and Pulmonary Complications -- Transfusion Associated Circulatory Overload -- Transfusion Associated Acute Lung Injury -- Conclusion -- References -- 8: The Effects of Hemoglobin-Based Oxygen Carriers (HBOC) on the Microcirculation -- Background -- Effects on the Microcirculation: A Hamster Skinfold Study -- Effects on the Microcirculation: A Canine Bulbar Conjunctiva Study -- Discussion -- References -- 9: Nitric Oxide and Hemoglobin: Physiological Implications -- Introduction -- Nitric Oxide Cardiovascular Effects -- Nitric Oxide Vascular Effects -- Nitric Oxide and Hemodynamic Regulations -- Hemoglobin (Hb) -- Interactions Between NO and Hemoglobin -- Nitrosyl Hemoglobin -- NO Bioactivity and Hemoglobin -- NO, Red Cell Biology and Blood Substitutes -- NO Scavenging -- Conclusion -- References -- 10: A Brief History of the Development of Nanobiotechnology-Based Blood Substitutes -- Introduction -- Hemolysate and Stroma Free Hemoglobin -- Early Basic Research on Nanobiotechnology Based RBC Substitute -- Polyhemoglobin Based on Nanobiotechnology -- First Generation Hemoglobin Based Oxygen Carriers (HBOCs) -- Four General Types of HBOCs -- Development During the HIV Contaminated Donor Blood Crisis -- Intramolecularly Crosslinked Hemoglobin -- Polyhemoglobin -- Glutaraldehyde Crosslinked Human PolyHb -- Glutaraldehyde Crosslinked Bovine PolyHb -- Conjugated Hemoglobin -- Nitric Oxide -- Inhalation of Nitric Oxide to Prevent Vasoconstriction -- Pyridoxalated Hemoglobin Polyoxyethylene as NO Scavenger in Distributive Shock -- Other Sources of Hemoglobin -- Bioengineering and Recombinant Methods -- Nanobiotechnology Based Oxygen Carriers with Antioxidant Functions -- Introduction -- PolyHb-CAT-SOD -- Convalently Binding of Nitroxides to PEG-Hb. Dual Carbon Monoxide and Oxygen Delivery Agent -- Vitamin C as Antioxidant -- Other Approaches -- Preservation for Transplant Organ -- Early Basic Research -- Light's Group -- Zal's Group -- Nanobiotechnology Based Oxygen Carriers with Enhancement of All Three RBC Functions -- Introduction -- Polyhemoglobin with Enhanced Catalase-Superoxide Dismutase-Carbonic Anhydrase -- Nanodimension Artificial Red Blood Cells -- Early Artificial Red Blood Cells -- Bilayer Lipid Membrane Nano Artificial RBC (Fig. 10.6) -- Nano-Dimension Biodegradable Polymeric Artificial Cells -- Variations in the Membrane and Configurations of Nano Artificial RBC -- Nonfunctional or Functional Membrane (Fig. 10.8) -- Other Areas -- Nanobiotechnology Based Oxygen Carrier with Platelet Function -- Nanobiotechnology Based Oxygen Carriers with Cancer Suppression Functions -- Stem Cells -- Future Development -- Summary Discussions -- What We Have Learned from Past History -- What Needs to Be Done -- References -- Part II: Pharmacology and Physiology of Oxygen Therapeutics -- 11: Classifications of Blood Substitutes -- Introduction -- Blood Composition -- Classification of Blood Substitutes -- Classification Based on the Blood Components -- Red Blood Cell Substitutes -- White Blood Cell (Leukocyte) Substitutes -- Platelet Substitutes -- Plasma Substitutes -- Classification of Erythrocyte Substitutes -- Hemoglobin-Based Oxygen Carriers -- Perfluorocarbon-Based Oxygen Carriers (PFBOC) -- Genetic Engineered Recombinant Hemoglobin -- Artificial and Cultured Red Blood Cells -- Erythrocyte Substitutes Classification Based on Hemoglobin Sources -- Erythrocyte Substitutes: Classification Based on RBC Membrane -- Erythrocyte Substitutes: Classification Based on Organic Molecule -- Erythrocyte Substitutes: Classification Based on Synthetic or Natural Molecule -- Ideal Erythrocyte Substitutes. Potential Indications for Blood Substitutes -- Summary -- References -- 12: Hemoglobin-Based Oxygen Carriers: Brief History, Pharmacology and Design Strategies, Review of the Major Products in Clinical Trials, On-Going Studies, and Coagulation Concerns -- Introduction -- Transfusion Medicine -- History of Hemoglobin-Based Oxygen Carriers -- How HBOCs Are Made -- Stroma Free Hemoglobin -- α-α Cross Linked Hb -- Glutaraldehyde Polymerized Hbs -- Recombinant HBOC -- Zero-Linked HBOCs -- Pegylated HBOCs -- Invertebrate Hb -- Pharmacology and Physiology of HBOCs -- Development of HBOCs -- Development of αα-Hb and HemAssist -- Development of Hemolink -- Development of Polyheme -- Development of Hemoximer -- Development of Hemopure and Summary/Discussion of Pivotal HEM-0115 Trial -- Adverse Events of Particular Interest -- Recent Clinical Trials on Hemopure -- Development of Third Generation HBOCs -- Coagulation and HBOCs -- Introduction -- Single Site Clinical Study of Hemopure on Platelet Function -- Summary of Hemopure -- Summary and Moving Forward -- References -- 13: Complications of HBOCs Including Clinical Safety Issues -- Introduction -- Criticism of the Natanson et al. Meta-Analysis -- Safety Aspects of Specific HBOCs -- HemAssist -- Optro -- Hemolink -- Polyheme -- MP40x-Hemospan ("3rd Generation") -- Hemopure (Biopure, OPK Pharma, HBO2 Therapeutics) -- Sanguinate (Prolong Pharmaceuticals) -- Adverse Events -- Conclusion -- References -- 14: On the Oxidative Toxicity of Hemoglobin -- Red Blood Cell Oxidation Reactions in Health and Disease: What Have We Learned? -- Oxidation of Hemoglobin and Cytosolic Antioxidative Proteins -- The Role of Red Cell Band 3 in Hemoglobin Oxidation -- Hemoglobin-Driven Oxidation Reactions Promote Microparticles Formation -- Role of β Cysteine 93 in Oxidative Stability of Hemoglobin. Genetically and Chemically Modified HBOCs: The Impact of Molecular Modifications. |
| Record Nr. | UNINA-9910586580103321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||